CY1119090T1 - Δευτεριωμενα παραγωγα ιβακαφτορης - Google Patents
Δευτεριωμενα παραγωγα ιβακαφτορηςInfo
- Publication number
- CY1119090T1 CY1119090T1 CY20171100584T CY171100584T CY1119090T1 CY 1119090 T1 CY1119090 T1 CY 1119090T1 CY 20171100584 T CY20171100584 T CY 20171100584T CY 171100584 T CY171100584 T CY 171100584T CY 1119090 T1 CY1119090 T1 CY 1119090T1
- Authority
- CY
- Cyprus
- Prior art keywords
- present
- ivakaftoris
- producers
- compositions
- administration
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487497P | 2011-05-18 | 2011-05-18 | |
| PCT/US2012/038297 WO2012158885A1 (en) | 2011-05-18 | 2012-05-17 | Deuterated derivatives of ivacaftor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119090T1 true CY1119090T1 (el) | 2018-01-10 |
Family
ID=46201810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100584T CY1119090T1 (el) | 2011-05-18 | 2017-06-02 | Δευτεριωμενα παραγωγα ιβακαφτορης |
| CY20191101275T CY1122498T1 (el) | 2011-05-18 | 2019-12-04 | Δευτεριωμενα παραγωγα ιβακαφτορης |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101275T CY1122498T1 (el) | 2011-05-18 | 2019-12-04 | Δευτεριωμενα παραγωγα ιβακαφτορης |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP3235812B1 (enExample) |
| JP (2) | JP6063455B2 (enExample) |
| AU (5) | AU2012255711B2 (enExample) |
| BR (1) | BR112013029240B1 (enExample) |
| CA (1) | CA2834574C (enExample) |
| CY (2) | CY1119090T1 (enExample) |
| DK (2) | DK2709986T3 (enExample) |
| EA (1) | EA028378B1 (enExample) |
| ES (2) | ES2628465T3 (enExample) |
| HR (2) | HRP20170754T1 (enExample) |
| HU (1) | HUE032771T2 (enExample) |
| LT (1) | LT2709986T (enExample) |
| ME (2) | ME02749B (enExample) |
| MX (1) | MX349159B (enExample) |
| PL (2) | PL2709986T3 (enExample) |
| PT (2) | PT2709986T (enExample) |
| RS (2) | RS56096B1 (enExample) |
| SI (2) | SI2709986T1 (enExample) |
| SM (2) | SMT201700302T1 (enExample) |
| WO (1) | WO2012158885A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55940B1 (sr) | 2005-12-28 | 2017-09-29 | Vertex Pharma | Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| ES2628465T3 (es) * | 2011-05-18 | 2017-08-02 | Concert Pharmaceuticals Inc. | Derivados deuterados de ivacaftor |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
| WO2013151758A2 (en) * | 2012-04-06 | 2013-10-10 | The Uab Research Foundation | Methods for increasing cftr activity |
| JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| MY183582A (en) * | 2012-11-19 | 2021-02-26 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
| DK3203840T3 (da) | 2014-10-06 | 2020-08-31 | Vertex Pharma | Modulatorer af cystisk fibrose-transmembrankonduktansregulator |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| EP3277647A1 (en) | 2015-03-31 | 2018-02-07 | Vertex Pharmaceuticals (Europe) Limited | Deuterated vx-661 |
| WO2017019589A1 (en) | 2015-07-24 | 2017-02-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| HK1258472A1 (zh) * | 2015-09-21 | 2019-11-15 | Vertex Pharmaceuticals (Europe) Limited | 氘代cftr增效剂的施用 |
| MA42954A (fr) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals Europe Ltd | Potentialisateurs cftr deutérés |
| CA3019663C (en) * | 2016-04-07 | 2024-09-24 | Proteostasis Therapeutics, Inc. | IVACAFTOR ANALOGUES CONTAINING SILICONE ATOMS |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| JP2017105824A (ja) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| KR102768380B1 (ko) | 2017-12-01 | 2025-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막관통 조절 인자의 제조 방법 |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| JP6654223B2 (ja) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド | 重水素化されたｃｆｔｒ増強物質 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| BR112022002606A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Moduladores do regulador de condutância transmembrana da fibrose cística |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| LV15575A (lv) | 2019-12-20 | 2021-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| JP2023537944A (ja) | 2020-08-13 | 2023-09-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒモジュレーターの結晶形態 |
| EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
| EP4225446A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL301755A (en) | 2020-10-07 | 2023-05-01 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230416275A1 (en) | 2020-10-07 | 2023-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373935A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20230107725A (ko) | 2020-10-07 | 2023-07-17 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| US20230365587A1 (en) | 2020-10-07 | 2023-11-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP2023545762A (ja) | 2020-10-07 | 2023-10-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 |
| EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373939A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| JP2025505577A (ja) | 2022-02-03 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | （６ａ，１２ａ）－１７－アミノ－１２－メチル－６，１５－ビス（トリフルオロメチル）－１３，１９－ジオキサ－３，４，１８－トリアザトリシクロ［１２．３．１．１２，５］ノナデカ－１（１８），２，４，１４，１６－ペンタエン－６－オールの調製方法及び結晶形態 |
| US20250221971A1 (en) | 2022-02-03 | 2025-07-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CR20240457A (es) | 2022-04-06 | 2024-12-11 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US20250332151A1 (en) | 2022-05-16 | 2025-10-30 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025166342A1 (en) | 2024-02-04 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis |
| US20250248981A1 (en) | 2024-02-07 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| BR0209325A (pt) | 2001-05-03 | 2004-07-20 | Hoffmann La Roche | Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| CA2810655C (en) * | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| CA2581169A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| CA2635214A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
| RS55940B1 (sr) | 2005-12-28 | 2017-09-29 | Vertex Pharma | Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
| ATE534383T1 (de) | 2006-05-12 | 2011-12-15 | Vertex Pharma | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid |
| AU2008299921B2 (en) * | 2007-09-13 | 2012-03-01 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| EP2328618B1 (en) | 2008-08-13 | 2017-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4- oxoquinoline-3-carboxamide and administration thereof |
| EP2337779B1 (en) * | 2008-09-03 | 2017-04-19 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| ES2628465T3 (es) * | 2011-05-18 | 2017-08-02 | Concert Pharmaceuticals Inc. | Derivados deuterados de ivacaftor |
-
2012
- 2012-05-17 ES ES12725197.3T patent/ES2628465T3/es active Active
- 2012-05-17 SI SI201230988A patent/SI2709986T1/sl unknown
- 2012-05-17 WO PCT/US2012/038297 patent/WO2012158885A1/en not_active Ceased
- 2012-05-17 RS RS20170601A patent/RS56096B1/sr unknown
- 2012-05-17 SI SI201231694T patent/SI3235812T1/sl unknown
- 2012-05-17 PT PT127251973T patent/PT2709986T/pt unknown
- 2012-05-17 EP EP17160386.3A patent/EP3235812B1/en active Active
- 2012-05-17 JP JP2014511524A patent/JP6063455B2/ja active Active
- 2012-05-17 ME MEP-2017-112A patent/ME02749B/me unknown
- 2012-05-17 PL PL12725197T patent/PL2709986T3/pl unknown
- 2012-05-17 CA CA2834574A patent/CA2834574C/en active Active
- 2012-05-17 HU HUE12725197A patent/HUE032771T2/en unknown
- 2012-05-17 ES ES17160386T patent/ES2758028T3/es active Active
- 2012-05-17 PT PT171603863T patent/PT3235812T/pt unknown
- 2012-05-17 DK DK12725197.3T patent/DK2709986T3/en active
- 2012-05-17 MX MX2013013450A patent/MX349159B/es active IP Right Grant
- 2012-05-17 EA EA201391615A patent/EA028378B1/ru unknown
- 2012-05-17 SM SM20170302T patent/SMT201700302T1/it unknown
- 2012-05-17 LT LTEP12725197.3T patent/LT2709986T/lt unknown
- 2012-05-17 RS RS20191494A patent/RS59744B1/sr unknown
- 2012-05-17 AU AU2012255711A patent/AU2012255711B2/en active Active
- 2012-05-17 BR BR112013029240-7A patent/BR112013029240B1/pt active IP Right Grant
- 2012-05-17 DK DK17160386T patent/DK3235812T3/da active
- 2012-05-17 HR HRP20170754TT patent/HRP20170754T1/hr unknown
- 2012-05-17 ME MEP-2019-325A patent/ME03652B/me unknown
- 2012-05-17 PL PL17160386T patent/PL3235812T3/pl unknown
- 2012-05-17 EP EP12725197.3A patent/EP2709986B1/en active Active
- 2012-05-17 SM SM20190679T patent/SMT201900679T1/it unknown
-
2016
- 2016-12-16 JP JP2016243941A patent/JP2017078082A/ja active Pending
-
2017
- 2017-06-02 CY CY20171100584T patent/CY1119090T1/el unknown
- 2017-07-27 AU AU2017208313A patent/AU2017208313A1/en not_active Abandoned
-
2019
- 2019-08-28 AU AU2019222862A patent/AU2019222862B2/en active Active
- 2019-11-25 HR HRP20192114TT patent/HRP20192114T1/hr unknown
- 2019-12-04 CY CY20191101275T patent/CY1122498T1/el unknown
-
2021
- 2021-02-15 AU AU2021200970A patent/AU2021200970B2/en active Active
- 2021-06-08 AU AU2021203786A patent/AU2021203786B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119090T1 (el) | Δευτεριωμενα παραγωγα ιβακαφτορης | |
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
| CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| CY1118842T1 (el) | Αναισθητικες ενωσεις και σχετιζομενες μεθοδοι χρησεις | |
| MY178621A (en) | Deuterated cftr potentiators | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201391568A1 (ru) | Новые производные имидазола, подходящие для лечения артрита | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| EA201490949A1 (ru) | Ингибиторы киназ | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| CY1124419T1 (el) | Συνθεσεις προφαρμακων φουμαρικου μονομεθυλεστερα |